Suministro controlado de tocilizumab durante la pandemia de COVID-19 e influencia sobre el tratamiento de pacientes reumatológicos
Background: Intravenous (IV) tocilizumab has been used to stop the inflammatory phase of SARS-CoV-2 infection. To preserve the largest number of IV units for this use, the Spanish Agency for Medicines and Health Products (AEMPS) carried out a controlled supply of it and recommended the change to a s...
Gespeichert in:
Veröffentlicht in: | Revista española de salud pública 2021 (95) |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | spa |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: Intravenous (IV) tocilizumab
has been used to stop the inflammatory phase of
SARS-CoV-2 infection. To preserve the largest
number of IV units for this use, the Spanish Agency
for Medicines and Health Products (AEMPS) carried
out a controlled supply of it and recommended
the change to a subcutaneous presentation (SC)
of tocilizumab or sarilumab in all those patients in
IV tocilizumab treatment for rheumatologic indications.
The objective of this study was to evaluate
the change from IV tocilizumab to SC presentation
due to its controlled supply during the COVID-19
pandemic.
Methods: Retrospective observational study of
adult patients (>18 years old) under treatment with
IV tocilizumab follow-up by the Rheumatology
Service of the Hospital 12 de Octubre. The follow-
up period was 3 months (March 2020-June
2020) and 39 patients were included in the study.
Variables related to the patients and their treatment
were collected. A descriptive analysis of the data
was carried out.
Results: In 69.23% (n=27) of the patients,
treatment was changed to SC tocilizumab (n=23) or
sarilumab (n=4). 44% of patients (n=12) switched
back to their original IV tocilizumab treatment. The
reasons for stopping treatment with SC tocilizumab
were: drug intolerance (n=4), disease worsening
(n=4), and patient preference (n=1). Regarding sarilumab,
the reasons were drug intolerance (n=2)
and patient preference (n=1).
Conclusions: Almost half of the patients had
to return to the original treatment. The main reason
was intolerance to the new treatment, followed by
ineffectiveness and patient preferences.
Fundamentos: El tocilizumab intravenoso
(IV) ha sido empleado para frenar la fase inflamatoria
de la infección por SARS-CoV-2. Para reservar
el mayor número de unidades IV para este uso,
la Agencia Española de Medicamentos y Productos
Sanitarios (AEMPS) realizó una distribución controlada
del mismo y recomendó el cambio a una
presentación subcutánea (SC), fuera tocilizumab
o sarilumab, en todos aquellos pacientes en tratamiento
con tocilizumab IV para indicaciones reumatológicas.
El objetivo de este trabajo fue evaluar
el cambio de tocilizumab IV a una presentación SC
debido a su suministro controlado durante la pandemia
de COVID-19.
Métodos: Se realizó un estudio observacional
retrospectivo de pacientes adultos (mayores
de 18 años) en tratamiento con tocilizumab IV en
seguimiento por el Servicio de Reumatología del
Hospital 12 de octubre (Madrid). El periodo de
seguimiento fue |
---|---|
ISSN: | 1135-5727 |